According to related industries, Bayer Korea's soluble guanylate cyclase (sGC) promoter Verquvo, which promotes the synthesis of intracellular cyclic monophosphate (cGMP), recently passed the HIRA. As a result, attention is focused on the future schedule of the Pharmaceutical Reimbursement Evaluation Committee.

In December 2021, death due to cardiovascular disease and hospitalization due to heart failure in patients with symptomatic chronic heart failure with a left ventricular ejection fraction lower than 45% who had recently been hospitalized for heart failure or received intravenous diuretics on an outpatient basis. It has been approved domestically as a combination therapy for risk reduction.